Dmitry N. Derkach M.D., Ph.D.

Dmitry N. Derkach, M.D., Ph.D. has a strong background in research and scientific roles. Dmitry N. began their work experience as a Post-Doctoral Research Associate at The University of Arizona in 2002, where they focused on establishing links between Myosin Light Chain phosphatase regulatory subunit MYPT1 and cGMP signaling in smooth muscle. During this time, they also discovered new functions of MYPT1 in cell kinetics.

In 2008, Dr. Derkach joined Capstone Therapeutics as a Research Scientist II. In this role, they developed and optimized various bioassays, including a cell-based assay for assessing TP508 drug potency, a fluorescence live cell-based assay for assessing AZX100 anti-fibrotic drug potency, and a reporter gene Luciferase-based assay for detecting fibrotic phenotypes.

In 2013, they transitioned to the Biodesign Institute as a Scientist. Dmitry N.'swork focused on scientific research until 2016, where they played a key role in the company's projects.

Dr. Derkach's most recent work experience has been as a Principal Scientist at bioSyntagma since 2015. Further details regarding their roles and responsibilities in this position are not provided.

Dmitry N. Derkach M.D., Ph.D. obtained their Doctor of Medicine (M.D.) degree in General Practice, Anesthesiology, and Critical Care from Perm State Medicine Academy named after E.A. Vagner (PSMA) during the years 1985 to 1993. Dmitry N. later pursued their postgraduate studies at Kyushu University, Graduate School of Medical Sciences from 1998 to 2002, where they obtained a Ph.D. in Integrative Biomedical Sciences with a focus on Molecular Biology in the Department of Molecular Cardiology.